Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Trial of Bortezomib in Combination With Thalidomide in Patients With Myelodysplasia

NCT00271804 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00271804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00271804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Trial of Bortezomib in Combination With Thalidomide in Patients With Myelodysplasia
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2005
Completion date
April 30, 2007
Enrollment
28
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome